Hong Kong Beverage Stock News

SEHK:23
SEHK:23Banks

Bank Of East Asia SEHK 23 Margin Compression Challenges Bullish Earnings Growth Narrative

Bank of East Asia (SEHK:23) has just posted its FY 2025 first half results, with total revenue of HK$7.7b and basic EPS of HK$0.86, alongside net income of HK$2.3b. The bank reported revenue of HK$7.5b and EPS of HK$0.69 in the first half of 2024, followed by revenue of HK$7.9b and EPS of HK$0.84 in the second half of 2024. As a result, FY 2025 starts after three consecutive reported periods of higher earnings per share. With that backdrop, investors are likely to focus on how its net...
SEHK:3738
SEHK:3738Software

Vobile Group (SEHK:3738) Valuation Check After Finloop IP Tokenization Collaboration

Vobile Group (SEHK:3738) has drawn fresh attention after announcing a collaboration with Finloop Finance Technology to tokenize offshore real world assets tied to cultural and creative intellectual property, with the aim of building a compliant IP backed digital asset ecosystem. See our latest analysis for Vobile Group. The Finloop agreement lands at a time when momentum in Vobile Group’s shares has been picking up, with a 7 day share price return of 37.09% and a year to date share price...
SEHK:1286
SEHK:1286Machinery

Undiscovered Gems in Asia to Explore This February 2026

As global markets navigate a mix of economic signals, with small-cap and value-oriented stocks gaining traction amidst concerns over artificial intelligence investments, Asia's market landscape presents unique opportunities for investors seeking potential growth. In this dynamic environment, identifying promising stocks often involves looking for companies that can capitalize on regional trends and demonstrate resilience in the face of broader market volatility.
SEHK:6855
SEHK:6855Biotechs

Ascentage China IND Clearance Puts BTK Degrader On Global Cancer Track

Ascentage Pharma Group International (SEHK:6855) received investigational new drug clearance in China for APG-3288, its next generation BTK targeted protein degrader. The Chinese clearance follows earlier U.S. FDA approval for clinical testing, aligning the program across two major drug development markets. APG-3288 is being developed for treatment resistant blood cancers, with a focus on hematologic malignancies that do not respond to existing BTK therapies. For investors tracking oncology...
SEHK:2172
SEHK:2172Medical Equipment

3 Asian Stocks Estimated Up To 29.3% Below Intrinsic Value

As global markets experience volatility influenced by concerns over artificial intelligence disruptions and geopolitical tensions, investors are increasingly turning their attention to value-oriented segments that have lagged behind the high-growth sectors. In Asia, this shift in focus has highlighted opportunities in undervalued stocks, which may present potential for growth as they trade below their intrinsic values. Identifying such stocks requires careful analysis of market conditions and...